| 1 | 08:00-08:05 |
Opening Remarks |
|
|||||
| 2 | 08:05-08:10 |
Opening Remarks |
|
|||||
| 1 | 08:10-08:25 |
Enfortumab Vedotin + Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Exploratory Analyses Based on Disease-Related Characteristics from EV-302 |
|
||||||||||||||||||||
| 2 | 08:25-08:40 |
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): Phase III CAPItello-281 Chinese subgroup analysis |
|
||||||||||||||||||||
| 3 | 08:40-08:55 |
Phase I clinical study of LACO-Stim modified targeted CD70 CAR-T cells in the treatment of metastatic renal clear cell carcinoma |
|
||||||||||||||||||||
| 4 | 08:55-09:10 |
Early precision prevention and control of lung cancer |
|
||||||||||||||||||||
| 5 | 09:10-09:25 |
Prospective, single-arm Phase II study of disitamab vedotin in locally advanced or metastatic extramammary Paget's disease with high HER2 expression (Formula-10) |
|
||||||||||||||||||||
| 6 | 09:25-09:40 |
Radioligand Therapy Clinical Trials: An Investigator and Drug Development Perspective |
|
||||||||||||||||||||
| 7 | 09:40-09:55 |
Discussion |
|
||||||||||||||||||||
| 1 | 09:55-10:10 |
Efficacy of debulking radical prostatectomy for patients with high tumor burden metastatic prostate cancer achieving deep PSA remission after systemic treatment: a prospective multicenter cohort study |
|
||||||||||||||||||||
| 2 | 10:10-10:25 |
Clinical exploration of posterior approach radical prostatectomy |
|
||||||||||||||||||||
| 3 | 10:25-10:40 |
Efficacy and Safety Evaluation of FANS f-URS Versus PCNL in the Treatment of 3-4cm Renal Stones - Preliminary Results of a Multi-Center Study |
|
||||||||||||||||||||
| 4 | 10:40-10:55 |
Study on the diagnostic efficacy of molecular imaging targeting CAⅨ in renal clear cell carcinoma |
|
||||||||||||||||||||
| 5 | 10:55-11:10 |
Intravesical Disitamab Vedotin (RC48) for BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Phase I Trial |
|
||||||||||||||||||||
| 6 | 11:10-11:25 |
Emerging therapies in NMIBC: from clinical trials to future practice |
|
||||||||||||||||||||
| 7 | 11:25-11:40 |
Discussion |
|
||||||||||||||||||||
| 1 | 11:40-12:30 |
Roundtable Discussion |
|
|||||||||||||||||||||||
| 1 | 13:30-13:36 |
Genomic and Epigenomic Approaches to Target Discovery and Therapeutic Development |
|
||||||||||||||||||||
| 2 | 13:36-13:42 |
Multimodal Fusion Ultrasound for Precision Navigation |
|
||||||||||||||||||||
| 3 | 13:42-13:48 |
Prospective Phase II Study of Neoadjuvant Targeted Immunotherapy Combined with Response-Adaptive Nephron-Sparing Strategy for High-Risk Upper Urinary Tract Urothelial Carcinoma |
|
||||||||||||||||||||
| 4 | 13:48-13:54 |
Ultrasound-guided balloon occlusion for hybrid partial nephrectomy: a non-randomized controlled trial |
|
||||||||||||||||||||
| 5 | 13:54-14:00 |
Precision antegrade robotic inguinal lymph node dissection under fluorescence imaging combined with color Doppler ultrasound localization |
|
||||||||||||||||||||
| 6 | 14:00-14:06 |
Artificial intelligence based augmented reality navigation in minimally invasive partial nephrectomy |
|
||||||||||||||||||||
| 7 | 14:06-14:12 |
Diagnostic efficacy and safety of PSMA-targeted near-infrared fluorescent contrast agent DGPR1008 in robotic-assisted radical prostatectomy: a single-center phase II clinical trial |
|
||||||||||||||||||||
| 8 | 14:12-14:18 |
Clinical research on bladder preservation with MIBC patients |
|
||||||||||||||||||||
| 9 | 14:18-14:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 14:30-14:36 |
Prospective, multicenter study on the non-invasive diagnosis of urothelial carcinoma through urine SIX6 methylation detection |
|
||||||||||||||||||||
| 2 | 14:36-14:42 |
Deficiencies in the diagnostic system for prostate cancer - A series of explorations to enhance the diagnostic accuracy of prostate cancer |
|
||||||||||||||||||||
| 3 | 14:42-14:48 |
Integrated diagnostic study of urine metabolomics combined with MRI radiomics in patients with prostate cancer |
|
||||||||||||||||||||
| 4 | 14:42-14:54 |
Urinary detection based on methylation for the diagnosis and recurrence monitoring of urothelial carcinoma: a multicenter, prospective clinical study |
|
||||||||||||||||||||
| 5 | 14:54-15:00 |
Application of dual-modal liquid biopsy based on CRISPR/Cas12a in precision diagnosis of prostate cancer |
|
||||||||||||||||||||
| 6 | 15:00-15:06 |
Multi-center research, development, and validation of UPGRADE-Dx: A non-invasive prostate cancer precision screening and biopsy guidance model based on low-abundance proteomics in urine |
|
||||||||||||||||||||
| 7 | 15:06-15:12 |
Combined application of GPR143, SV2B, and NMRK2 immunohistochemical markers effectively distinguishes TFE3-rearranged renal cell carcinoma from renal clear cell carcinoma and papillary renal cell carcinoma: a multicenter study |
|
||||||||||||||||||||
| 8 | 15:12-15:18 |
Research on the application value of MRI artificial intelligence in precise biopsy diagnosis of prostate cancer: a prospective diagnostic trial |
|
||||||||||||||||||||
| 9 | 15:18-15:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 15:30-15:36 |
Study on the necessity of pelvic lymph node dissection in radical cystectomy for high-risk non-muscle-invasive bladder cancer - a prospective multicenter study |
|
||||||||||||||||||||
| 2 | 15:36-15:42 |
Darolutamide combined with ADT versus Bicalutamide combined with ADT as adjuvant therapy after radical surgery for high-risk localized prostate cancer: Interim analysis |
|
||||||||||||||||||||
| 3 | 15:42-15:48 |
Efficacy and safety of a domestic water vapor thermal therapy system in patients with benign prostatic hyperplasia: a prospective, multicenter, single-blind, randomized controlled trial |
|
||||||||||||||||||||
| 4 | 15:48-15:54 |
The effect of a treatment method based on lipus innovative technology on the recovery of urinary incontinence after radical androgen deprivation therapy (RARP): a randomized, double-blind, prospective, multicenter clinical trial |
|
||||||||||||||||||||
| 5 | 15:54-16:00 |
A multi-center randomized controlled study on percutaneous nephrolithotomy guided by CT-ultrasound fusion and conventional ultrasound |
|
||||||||||||||||||||
| 6 | 16:00-16:06 |
Safety study of autologous dendritic cell vaccine Prolevis in metastatic castration-resistant prostate cancer patients who have failed standard treatment: a multicenter, non-randomized, open-label, dose-escalation Phase I clinical trial |
|
||||||||||||||||||||
| 7 | 16:06-16:12 |
Evaluation of early efficacy of domestic prostate suspension system in the treatment of benign prostatic hyperplasia: a multicenter prospective randomized parallel controlled study |
|
||||||||||||||||||||
| 8 | 16:12-16:18 |
A prospective, multicenter, randomized controlled clinical trial on the prevention of GnRH agonist-induced flare-up effects with rivarubicin |
|
||||||||||||||||||||
| 9 | 16:18-16:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 16:30-16:36 |
Application of Prostate-Specific Membrane Antigen (PSMA) PET/MRI-Guided Targeted Prostate Biopsy in Patients with PI-RADS Score ≤3 and Previous Negative Biopsy: A Single-Center, Prospective, Open-Label, Randomized Controlled Study |
|
||||||||||||||||||||
| 2 | 16:36-16:42 |
Tislelizumab Combined with Radiotherapy for Bladder Preservation in High-Risk Non-Muscle-Invasive Bladder Cancer Following BCG Failure: A Single-Arm, Phase 2 Clinical Trial |
|
||||||||||||||||||||
| 3 | 16:42-16:48 |
resection followed by sequential endocrine therapy for high tumor burden metastatic prostate cancer: a single-center prospective non-randomized controlled study |
|
||||||||||||||||||||
| 4 | 16:48-16:54 |
Phase II clinical study of CD70 immuno-PET imaging for the diagnosis of renal clear cell carcinoma |
|
||||||||||||||||||||
| 5 | 16:54-17:00 |
Prospective randomized clinical study on the selection of bladder instillation chemotherapy drugs guided by patient-derived tumor-like cell clusters after surgery for non-muscle-invasive bladder cancer |
|
||||||||||||||||||||
| 6 | 17:00-17:06 |
Phase Ia clinical trial of intravesical instillation of recombinant oncolytic adenovirus KD01 for the treatment of high-risk non-muscle-invasive bladder cancer: a single-center, open-label, non-randomized study |
|
||||||||||||||||||||
| 7 | 17:06-17:12 |
Detection characteristics of prostatic intraductal carcinoma and its association with biochemical recurrence after radical prostatectomy: a single-center retrospective study based on 7060 specimens |
|
||||||||||||||||||||
| 8 | 17:12-17:18 |
The application value of targeted biopsy based on real-time radioactive measurement with 123I-PSMA-7 in the diagnosis of clinically significant prostate cancer: a single-center prospective exploratory study |
|
||||||||||||||||||||
| 9 | 17:18-17:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 17:30-17:36 |
Research on Prostate Biopsy Decision-making Model Based on Morning Urine PCA3 and mpMRI Features |
|
||||||||||||||||||||
| 2 | 17:36-17:42 |
Single-center, retrospective cohort analysis of pelvic lipomatosis - Renji experience |
|
||||||||||||||||||||
| 3 | 17:42-17:48 |
The current application status and pathological benefits of lymph node dissection in radical prostatectomy: a retrospective study based on 1861 cases from a single center |
|
||||||||||||||||||||
| 4 | 17:48-17:54 |
High-frequency mutations and genotype-phenotype analysis of the VHL gene: a retrospective study based on 820 Chinese patients with von Hippel-Lindau syndrome |
|
||||||||||||||||||||
| 5 | 17:54-18:00 |
A 12-year multicenter review of laparoscopic or robotic-assisted laparoscopic endovascular stenting for the treatment of type 1 nutcracker syndrome |
|
||||||||||||||||||||
| 6 | 18:00-18:06 |
Clinical Research on the Treatment of Ureteral Polyp with Lingual Mucosa Ureteroplasty |
|
||||||||||||||||||||
| 7 | 18:06-18:12 |
Analysis of clinical epidemiological characteristics and regional heterogeneity of prostate cancer in Jiangsu Province: based on a survey of 3,717 patients from 17 centers |
|
||||||||||||||||||||
| 8 | 18:12-18:18 |
The prognostic significance of pathological nerve invasion in prostate cancer: when coexistent with positive resection margins, it significantly promotes castration-resistant transformation, a multi-center ten-year follow-up study |
|
||||||||||||||||||||
| 9 | 18:18-18:24 |
Preliminary clinical observation on the safety and efficacy of Rezūm® thermal vapor ablation therapy in patients with benign prostatic hyperplasia and comorbid high-risk cardiovascular diseases: a single-arm, single-center retrospective study |
|
||||||||||||||||||||
| 10 | 18:24-18:36 |
Discussion |
|
||||||||||||||||||||